

Global Managed Access Program Policy

Agios is committed to supporting patients and their families seeking to explore all available treatment options. Individuals currently diagnosed with Pyruvate kinase (PK) deficiency who are unable to access treatment may be eligible for treatment through our Global Managed Access Program when certain criteria are met. These criteria include, but are not limited to:

- The person has a current diagnosis of Pyruvate kinase (PK) deficiency
- The person is 18 years of age or older
- The person does not have rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
- Sufficient supply of PYRUKYND is readily available and supply is allowed under the local rules and regulations
- Other criteria may be considered and reviewed with the treating provider based on the assessment of the person's condition and medical history

Requesting Access:

Agios is committed to evaluating all requests in a fair and equitable manner and in consultation with qualified treating providers.

To obtain access to PYRUKYND, a provider must first confirm the criteria outlined above have been met and then may submit a formal treatment request. If the request is approved, the provider assumes responsibility for the management of the patient's care, including the reporting of any adverse events, during the duration of treatment. Each request will be evaluated based on the information submitted by, and in consultation with, the provider related to the patient's condition and medical history.

Providers may submit a formal request on behalf of their patient to Agios for consideration at expandedaccess@agios.com. Requests will be acknowledged within 2 business days of receipt.